ARAYMEDIUM SIGNALFINANCIAL10-K

Accuray substantially reduced its net loss while strengthening its balance sheet through debt reduction and improved equity position.

The dramatic improvement in net loss combined with meaningful debt reduction suggests the company has made significant progress on operational efficiency and financial discipline. The 12% increase in outstanding shares indicates some equity financing activity, which along with improved profitability helped strengthen the balance sheet position.

Comparing 2025-08-28 vs 2024-09-19View on EDGAR →
FINANCIAL ANALYSIS

Accuray demonstrated meaningful financial improvement with net losses substantially reduced from $15.5M to $1.6M year-over-year. The company strengthened its balance sheet by reducing total debt 21% to $136.5M while stockholders' equity grew 80% to $81.2M, though cash declined modestly to $57.4M. The overall picture signals improved operational performance and enhanced financial stability through both earnings improvement and debt reduction.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+89.8%
-$15.5M→-$1.6M

Net income grew 89.8% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
+80%
$45.1M→$81.2M

Equity base grew 80% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Debt
Balance Sheet
-20.7%
$172.2M→$136.5M

Debt reduced 20.7% — deleveraging strengthens balance sheet and reduces financial risk.

Cash & Equivalents
Balance Sheet
-16.3%
$68.6M→$57.4M

Cash decreased 16.3% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2025-08-28
PRIOR — 2024-09-19
ADDED
As of August 22, 2025, the nu mber of outstanding shares of the registrant s common stock, $0.001 par value, was 112,677,147 .
Advanced architecture that accommodates third party surface guidance interfaces to support effective positioning of the patient and monitoring of the accuracy of that positioning throughout treatment, and enable deep inspiration breath hold ( DIBH ) for highly accurate and precise breast cancer treatments.
We believe our current technologies and our future innovations can help to achieve this.
Many of the countries in these regions are not highly developed at this time and therefore sales opportunities may be limited.
In addition, we recently introduced Accuray Helix, a CT-guided helical radiotherapy system, to help address gaps in patient access to radiation medicine.
+7 more — sign up free →
REMOVED
As of August 31, 2024, the number of outstanding shares of the registrant s common stock, $0.001 par value, was 100,267,900 .
Advanced architecture that accommodates third party surface guidance interfaces that can enable deep inspiration breath hold ( DIBH ) for highly accurate and precise breast treatments.
We endeavor to achieve this goal by expanding the clinical options for healthcare providers, helping them offer the best radiation treatment for each patient and by providing patients with treatment tailored to their specific needs.
Many of these countries however, are not highly developed at this time and therefore, sales opportunities may be limited.
In fiscal 2021, we announced a collaboration with Brainlab to enhance and expand the CyberKnife platform s capabilities for the neuro-radiosurgery market.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →